List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9143908/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EUR <i>Observational</i> Research Programme: regional differences and 1â€year followâ€up results of the Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2013, 15, 808-817.	7.1	645
2	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2013, 15, 1173-1184.	7.1	533
3	EUR <i>Observational</i> Research Programme: The Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2010, 12, 1076-1084.	7.1	340
4	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC: Heart Failure, 2018, 6, 452-462.	4.1	94
5	Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. European Heart Journal, 2010, 31, 3084-3093.	2.2	55
6	Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction. Scientific Reports, 2018, 8, 9883.	3.3	48
7	Progeroid syndrome with sclerodermaâ€like skin changes associated with homozygous R435C <i>LMNA</i> mutation. American Journal of Medical Genetics, Part A, 2009, 149A, 2387-2392.	1.2	28
8	Endoscopic study of the morphology of Vieussens valve. Clinical Anatomy, 2004, 17, 318-321.	2.7	27
9	Heart failure in COVIDâ€19: the multicentre, multinational PCHFâ€COVICAV registry. ESC Heart Failure, 2021, 8, 4955-4967.	3.1	26
10	Anemia at Hospital Admission and Its Relation to Outcomes in Patients With Heart Failure (from the) Tj ETQq0 C Cardiology, 2017, 119, 2021-2029.) 0 rgBT /0 1.6	verlock 10 Tf 21
11	Clinical characteristics and predictors of one-year outcome of heart failure patients with atrial fibrillation compared to heart failure patients in sinus rhythm. Kardiologia Polska, 2016, 74, 251-261.	0.6	21
12	Circulating tenascin-C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy. Clinica Chimica Acta, 2011, 412, 1533-1538.	1.1	18
13	Diagnosis, Clinical Course, and 1-Year Outcome in Patients Hospitalized for Heart Failure With Preserved Ejection Fraction (from the Polish Cohort of the European Society of Cardiology Heart) Tj ETQq1 1 0.7	'84 <u>₿</u> ቆ4 rgl	3T Øverlock
14	Predictors of one-year outcome in patients hospitalised for heart failure: results from the Polish part of the Heart Failure Pilot Survey of the European Society of Cardiology. Kardiologia Polska, 2016, 74, 9-17.	0.6	15
15	Ischemic Cardiomyopathy versus Non-Ischemic Dilated Cardiomyopathy in Patients with Reduced Ejection Fraction— Clinical Characteristics and Prognosis Depending on Heart Failure Etiology (Data) Tj ETQq1	1 0 88431	14 Ig BT /Ovei
16	Myocarditis and inflammatory cardiomyopathy in 2021 – an update. Polish Archives of Internal Medicine, 2021, 131, 594-606.	0.4	14
17	Limb-girdle muscular dystrophy with severe heart failure overlapping with lipodystrophy in a patient with LMNA mutation p.Ser334del. Journal of Applied Genetics, 2017, 58, 87-91.	1.9	12
18	Cardiac Arrhythmias in Muscular Dystrophies Associated with Emerinopathy and Laminopathy: A Cohort Study. Journal of Clinical Medicine, 2021, 10, 732.	2.4	12

#	Article	IF	CITATIONS
19	Cardiac pacing in 21 patients with Emery-Dreifuss muscular dystrophy: a single-centre study with a 39-year follow-up. Kardiologia Polska, 2016, 74, 576-583.	0.6	11
20	Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. Cardiovascular Drugs and Therapy, 2019, 33, 77-86.	2.6	10
21	Matrix metalloproteinases in serum of Emery-Dreifuss muscular dystrophy patients Acta Biochimica Polonica, 2009, 56, .	0.5	10
22	Echocardiographic Features of Cardiomyopathy in Emery-Dreifuss Muscular Dystrophy. Cardiology Research and Practice, 2021, 2021, 1-7.	1.1	9
23	Common carotid artery access for transcatheter aortic valve implantation. Kardiologia Polska, 2015, 73, 478-484.	0.6	9
24	Quality of care of hospitalised patients with heart failure in Poland in 2013: results of the second nationwide survey. Kardiologia Polska, 2017, 75, 527-534.	0.6	9
25	Dual antiplatelet therapy is safe and efficient after left atrial appendage closure. Kardiologia Polska, 2018, 76, 459-463.	0.6	9
26	Heart failure in elderly patients: differences in clinical characteristics and predictors of 1-year outcome in the Polish ESC-HF Long-Term Registry. Polish Archives of Internal Medicine, 2016, 126, 502-13.	0.4	9
27	Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art. Biology, 2022, 11, 288.	2.8	9
28	X-Linked Emery–Dreifuss Muscular Dystrophy: Study Of X-Chromosome Inactivation and Its Relation with Clinical Phenotypes in Female Carriers. Genes, 2019, 10, 919.	2.4	8
29	Diastolic dysfunction of the left ventricle – a practical approach for an anaesthetist. Anaesthesiology Intensive Therapy, 2020, 52, 237-244.	1.0	8
30	Low-symptomatic skeletal muscle disease in patients with a cardiac disease – Diagnostic approach in skeletal muscle laminopathies. Neurologia I Neurochirurgia Polska, 2018, 52, 174-180.	1.2	7
31	Differences in clinical characteristics and one-year outcomes of hospitalized heart failure patients in succeeding European Society of Cardiology-Heart Failure Registries – Pilot and Long-Term. Polish Archives of Internal Medicine, 2019, 129, 106-116.	0.4	7
32	Emery-Dreifuss dystrophy: a 4-year follow-up on a laminopathy of special interest. Neurologia I Neurochirurgia Polska, 2009, 43, 415-20.	1.2	7
33	Osteopontin – a fibrosis-related marker – in dilated cardiomyopathy in patients with Emery-Dreifuss muscular dystrophy. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 658-662.	1.2	6
34	Chronic heart failure management in primary healthcare in Poland: Results of a nationwide cross-sectional study. European Journal of General Practice, 2018, 24, 1-8.	2.0	6
35	Resting heart rate at hospital admission and its relation to hospital outcome in patients with heart failure. Cardiology Journal, 2014, 21, 425-433.	1.2	6
36	Heart Team for Optimal Management of Patients with Severe Aortic Stenosis—Long-Term Outcomes and Quality of Life from Tertiary Cardiovascular Care Center. Journal of Clinical Medicine, 2021, 10, 5408.	2.4	6

#	Article	IF	CITATIONS
37	Dysfunctional lamins as mediators of oxidative stress in Emery-Dreifuss muscular dystrophy. Folia Neuropathologica, 2017, 3, 193-198.	1.2	5
38	Do β-blockers improve one-year survival in heart failure patients with atrial fibrillation? Results from the ESC-HF Registry. Polish Archives of Internal Medicine, 2018, 128, 649-657.	0.4	5
39	In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term Registries. Cardiology Journal, 2020, 27, 25-37.	1.2	5
40	Reverse Takotsubo syndrome in a patient with diagnosed multiple sclerosis. Kardiologia Polska, 2016, 74, 1029-1029.	0.6	5
41	Clinical characteristics and 1-year outcome of hyponatremic patients hospitalized for heart failure. Polish Archives of Internal Medicine, 2015, 125, 120-131.	0.4	5
42	Optimal Management of Patients with Severe Coronary Artery Disease following Multidisciplinary Heart Team Approach—Insights from Tertiary Cardiovascular Care Center. International Journal of Environmental Research and Public Health, 2022, 19, 3933.	2.6	5
43	The prevalence and association of major ECG abnormalities with clinical characteristics and the outcomes of real-life heart failure patients — Heart Failure Registries of the Eu ropean Society of Cardiology. Kardiologia Polska, 2021, 79, 980-987.	0.6	4
44	Healthcare professionals' knowledge on cardiopulmonary resuscitation correlated with return of spontaneous circulation rates after in-hospital cardiac arrests: A multicentric study between university hospitals in 12 European countries. European Journal of Cardiovascular Nursing, 2020, 19, 401-410.	0.9	4
45	A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus-negative myocarditis or inflammatory cardiomyopathy (IMPROVE-MC). Cardiology Journal, 2022, 29, 329-341.	1.2	4
46	Left Ventricular Outflow Obstruction After TAVR Due to Systolic Anterior Motion Successfully Treated With Cardiac Pacing. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 2718-2721.	1.3	3
47	Cardiac Resynchronization Therapy in Patients with Heart Failure. Heart Failure Clinics, 2021, 17, 289-301.	2.1	3
48	Expression of versican mRNA transcript to predict cardiac remodelling after myocardial infarction. Kardiologia Polska, 2021, 79, 833-840.	0.6	3
49	Low symptomatic malignant cardiac arrhythmia in a patient with lamin-related congenital muscular dystrophy. Kardiologia Polska, 2015, 73, 942-942.	0.6	3
50	Tissue inhibitors of matrix metalloproteinases in serum are cardiac biomarkers in Emery-Dreifuss muscular dystrophy. Kardiologia Polska, 2015, 73, 360-365.	0.6	3
51	Heart failure management in Poland: The National Cardiovascular Disease Prevention and Treatment Program POLKARD, edition 2003-2005. Cardiology Journal, 2007, 14, 552-60.	1.2	3
52	Access to selected diagnostic procedures in the management of heart failure patients in Poland - POLKARD 2005. Kardiologia Polska, 2010, 68, 265-72.	0.6	3
53	Long-term outcomes and quality of life following implementation of dedicated mitral valve Heart Team decisions for patients with severe mitral valve regurgitation in tertiary cardiovascular care center. Cardiology Journal, 2024, 31, 62-71.	1.2	3
54	Predictors of mortality and cardiovascular outcomes in Emery-Dreifuss muscular dystrophy in a long-term follow-up. Kardiologia Polska, 2021, 79, 1335-1342.	0.6	3

#	Article	IF	CITATIONS
55	Atrial fi brillation as a fi rst clinical manifestation of right atrial cavernous haemangioma. Acta Cardiologica, 2013, 68, 197-199.	0.9	2
56	Fifteen-Year Differences in Indications for Cardiac Resynchronization Therapy in International Guidelines—Insights from the Heart Failure Registries of the European Society of Cardiology. Journal of Clinical Medicine, 2022, 11, 3236.	2.4	2
57	Cardiovascular risk markers in dilated cardiomyopathy in Emery–Dreifuss muscular dystrophy (EDMD). International Journal of Cardiology, 2014, 173, 324-325.	1.7	1
58	Severe mitral stenosis secondary to eosinophilic granulomatosis resolving after pharmacological treatment. Echocardiography, 2018, 35, 2099-2103.	0.9	1
59	Simultaneous valve-in-valve procedure and life-saving coronary angioplasty in a patient with low coronary artery ostia. Postepy W Kardiologii Interwencyjnej, 2021, 17, 234-235.	0.2	1
60	Heart failure patients with a previous coronary revascularization: results from the ESC-HF Registry. Kardiologia Polska, 2018, 76, 144-152.	0.6	1
61	An Individualized Approach of Multidisciplinary Heart Team for Myocardial Revascularization and Valvular Heart Disease—State of Art. Journal of Personalized Medicine, 2022, 12, 705.	2.5	1
62	Direct visualization of the coronary sinus ostium and branches. Heart Rhythm, 2005, 2, 1276.	0.7	0
63	Usage and utility of PFA-100 and cone NAD platelet analyzer impact-R for testing platelet function. Journal of Molecular and Cellular Cardiology, 2007, 42, S234.	1.9	0
64	Utility of platelet function analyzer Pfa-100 in assessment of platelet function in patients with stable coronary artery. Journal of Molecular and Cellular Cardiology, 2007, 42, S235.	1.9	0
65	Cardiac involvement in laminopathies – short invited review. Family Medicine and Primary Care Review, 2015, 4, 327-329.	0.2	0
66	Left Ventricular Outflow Tract Obstruction Due to Elongation of Anterior Mitral Leaflet. Circulation: Cardiovascular Imaging, 2019, 12, e009524.	2.6	0
67	789 Treadmill test is a useful tool for rate control strategy in permanent atrial fibrillation. European Journal of Heart Failure, Supplement, 2007, 6, 180-180.	0.0	0
68	717 Cardiomyopathy associated with Emery-Dreifuss muscular dystrophy, echocardiographic and biomarker study. European Journal of Heart Failure, Supplement, 2007, 6, 159-159.	0.0	0
69	277 Rhythm control strategy improves exercise tolerance and left ventricular function in patients with persistent atrial fibrillation. European Journal of Heart Failure, Supplement, 2007, 6, 57-57.	0.0	0
70	96 Concomitant estimation of NT-pro-BNP and CA125 for better outcome prognosis in congestive heart failure. European Journal of Heart Failure, Supplement, 2007, 6, 22-22.	0.0	0
71	Atypical findings in the left ventricular outflow tract in a patient with hypertrophic cardiomyopathy. Cardiology Journal, 2019, 26, 414-415.	1.2	0